Document:

Exhibit 4.1

THE BANK OF NEW YORK MELLON

NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON

 

 

240 Greenwich
Street, 22W Floor, New York, NY 10286

 

 

 

October 14, 2022

 

Hennion & Walsh, Inc.

2001 Route 46, Waterview Plaza

Parsippany, New Jersey 07054

 

SmartTrust 586 (the “Fund”)

 

Dear Sirs:

The Bank of New York Mellon
is acting as trustee for the Fund, consisting of the unit investment trust (the “Trust”) included in the Registration
Statement relating to the Fund. We enclosed a list of the securities to be deposited in the Trust on the date hereof. The prices indicated
therein reflect our evaluation of such securities as of close of business on October 13, 2022, in accordance with the valuation method
set forth in the applicable Standard Terms and Conditions of Trust and Trust Agreement. We consent to the reference to The Bank of New
York Mellon as the party performing the evaluations of the Trust securities in the Registration Statement (No. 333-266192) filed with
the Securities and Exchange Commission with respect to the registration of the sale of the Units of the Trust and to the filing of this
consent as an exhibit thereto.

 

Very truly yours,

 

/s/  Margarita
Kalantarova

Margarita Kalantarova

Vice PresidentExhibit 4.3

Consent of Independent Registered Public
Accounting Firm

We have issued our report
dated October 14, 2022, with respect to the financial statement of SmartTrust 586 contained in Amendment No. 1 to the Registration Statement
on Form S-6 (File No. 333-266192) and related Prospectus. We consent to the use of the aforementioned report in the Registration Statement
and Prospectus, and to the use of our name as it appears under the caption “Independent Registered Public Accounting Firm”.

 

/s/ Grant
Thornton LLP

 

Chicago, Illinois

October 14, 2022Exhibit 10.1

 

AMENDED
AND RESTATED license AND SERVICES AGREEMENT

 

This AMENDED AND RESTATED
LICENSE AND Services AGREEMENT (this “Agreement”) is entered into as
of October 11, 2022 (the “Restatement Date”) by and among Jaguar Health, Inc., a Delaware corporation (“Licensor”),
SynWorld Technologies Corporation, a corporation duly incorporated under the laws of Canada (“Licensee”), solely for
purposes of Sections 9.4 (Representations and Warranties of Licensee, Licensee Guarantor and Parent), 10.3 (Indemnification
by Licensee Guarantor and Parent) and 13.13 (Guaranty), C&E Telecom, LTD, a company organized under the laws of
the British Virgin Islands (“Licensee Guarantor”), and, solely for purposes of Sections 9.4 (Representations
and Warranties of Licensee, Licensee Guarantor and Parent) and 10.3 (Indemnification by Licensee Guarantor and Parent),
Tao Wang, an individual (“Parent”). Licensor and Licensee and, solely for purposes of Article 10 (Indemnification;
Liability; Insurance), Licensee Guarantor and Parent are referred to in this Agreement individually as a “Party”
and collectively as the “Parties.”

 

Recitals

 

WHEREAS,
Licensor has certain intellectual property rights with respect to Crofelemer and the Product;

 

WHEREAS,
the Parties previously entered into that certain License and Services Agreement, dated as of June 28, 2022 (the “Effective
Date”), as amended by that certain First Amendment to the License and Services Agreement, dated as of August 18, 2022,
by and between Licensor and Licensee (the “Original Agreement”), pursuant to which Licensee (i) granted to Licensee
certain licenses to significantly improve and/or expand the scope of Licensor’s intellectual property rights, including in respect
of the Product, and to commercialize the Product and (ii) engaged Licensee to obtain regulatory approval for the Product to treat
all forms of diarrhea in dogs in the Licensee Territory, in each case pursuant to the terms and conditions of the Original Agreement;
and

 

WHEREAS,
the Parties desire to amend and restate the Original Agreement in its entirety as of the Restatement Date.

 

Agreement

 

NOW, THEREFORE, in consideration
of the foregoing and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby
agree that the Original Agreement is hereby amended and restated in its entirety as follows:

 

1.             Definitions

 

“Affiliate”
means, with respect to a Party, any person or entity that directly or indirectly, through one or more intermediates, controls, is controlled
by, or is under common control with such Party. For the purpose of this definition, “control” means the direct or indirect
ownership of: (i) fifty percent (50%) or more of the capital stock or share capital entitled to vote for the election of directors
of the entity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction),
(ii) fifty percent (50%) or more of the equity or voting interest of the entity (or such lesser percentage which is the maximum allowed
to be owned by a foreign corporation in a particular jurisdiction), or (iii) status as a general partner in any partnership; in each
case, whereby such person or entity controls or has the right to control the board of directors or equivalent governing body of a corporation
or other entity. An entity will be an Affiliate for purposes of this Agreement only so long as it satisfies the definition set forth herein.

 

    	 	1	 

     

    

 

“Bankruptcy Code”
means the U.S. Bankruptcy Code (in the United States of America), as amended from time to time, and the rules and regulations and
guidelines promulgated thereunder, or any applicable bankruptcy laws of any other country or competent Governmental Authority, as amended
from time to time, and the rules and regulations and guidelines promulgated thereunder.

 

“Business Day”
means any day other than a Saturday, Sunday or any day on which banks located in the United States of America are authorized or obligated
to close.

 

“Calendar
Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31,
except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which
the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and
end on the last day of the Term.

 

“CFIUS”
has the meaning set forth in Section 9.3(h).

 

“Claims”
has the meaning set forth in Section 10.1.

 

“Clinical Study”
means any study conducted in animals (healthy participants or patients) according to a set protocol and meeting the requirements of GCP.

 

“Collaboration Manager”
has the meaning set forth in Section 3.1.

 

“Commercialization,”
 “Commercialize” or “Commercializing” means, with respect to a given product, all activities undertaken
before or after obtaining Regulatory Approvals relating to the pre-launch, launch, promotion, detailing, medical education and medical
liaison activities, branding, marketing, advertising, pricing, reimbursement, offering for sale, sale and distribution of such product,
including product support, life cycle management, patient support, customer support, the booking of sales, safety monitoring, sampling,
shipping, handling, warehousing, logistics management and invoicing activities. “Commercialization” excludes any Development
or manufacture of such product.

 

“Commercialization
Plan” has the meaning set forth in Section 6.1.

 

“Common Stock”
means shares of voting common stock, par value $0.0001 per share, of the Licensor.

 

    	 	2	 

     

    

 

“Confidential Information”
means all information disclosed, directly or indirectly, by the Disclosing Party to the Receiving Party during the Term or prior to the
Effective Date that is identified as confidential or is customarily regarded as confidential within the pharmaceutical industry, whether
disclosed in electronic, tangible, oral or visual form. To the extent practical, Confidential Information shall be disclosed in tangible
form and marked “Confidential.” The existence of this Agreement and the terms hereof shall be deemed to be “Confidential
Information” of each Party. Confidential Information shall not include such information that: (1) was or becomes generally
available to the public other than as a result of an unauthorized disclosure by the Receiving Party or any of Receiving Party’s
Affiliates, employees, agents or representatives; (2) was or becomes available to the Receiving Party or any of Receiving Party’s
Affiliates on a non-confidential basis from a source other than the Disclosing Party (or any of Disclosing Party’s Affiliates, employees,
agents or representatives); or (3) has been disclosed to the Receiving Party without restrictions or other protection against public
disclosure; provided that such source was not known by the Receiving Party or its Affiliates to be bound by any agreement to keep
such information confidential or otherwise prohibited from transmitting the information by a contractual, legal or fiduciary obligation.
Information that is otherwise Confidential Information and consists of a combination of elements shall not be deemed to be in the public
domain merely because individual elements of such information are in the public domain, unless the specific combination of those elements
is also in the public domain.

 

“Control”
or “Controlled” means, with respect to any material, Information, or intellectual property right, that a Party
(a) owns or (b) has a license or other right (other than a license granted to such Party under this Agreement) to use, assign
or grant a license or other right to or under such material, Information, or intellectual property right, and, in each case, has
the ability to grant to the other Party access, a license or a sublicense (as applicable) to the foregoing on the terms and conditions
set forth in this Agreement without violating the terms of any then-existing agreement or other arrangement with any Third Party.

 

“Crofelemer”
means oligomeric proanthocyanidin (OPC) containing catechin, epicatechin, gallocatechin, and epigallocatechin randomly sequenced in chain
lengths ranging from n=3 to n=30 with an average molecular weight of approximately 2000 daltons, including any Improvements thereto.

 

“Deliverables”
has the meaning set forth in Section 5.3.

 

“Develop,”
 “Developing” or “Development” means, with respect to a given product, all activities that are necessary
or useful to obtain, support or maintain Regulatory Approval (other than to obtain any pricing or reimbursement approvals) of such product
in any particular country or jurisdiction in the Licensee Territory, including any such activities relating to preparing and conducting
pre-clinical studies, non-clinical studies and Clinical Studies and regulatory activities (e.g., preparing, filing and obtaining regulatory
applications). “Develop” or “Development” excludes the Commercialization and the manufacture of such product.

 

“Disclosing Party”
has the meaning set forth in Section 11.1(a).

 

“Dispute”
has the meaning set forth in Section 13.4.

 

“Dollar”
means U.S. dollars, and “$” shall be interpreted accordingly.

 

“European Union”
means, at any particular time, all countries that are then officially recognized as member states of the European Union or members of
the European Economic Area.

 

    	 	3	 

     

    

 

“Exchange Act”
means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exchange Cap”
means the maximum number of shares of Common Stock that could be issued to Licensee without violating The Nasdaq Capital Market rules related
to the aggregation of offerings under Nasdaq Listing Rule 5635(d), if applicable.

 

“Generic Product”
means, with respect to the Product, any product that is approved, or is sought to be approved, under an Abbreviated New Drug Application,
and in reliance, in whole or in part, on the prior approval (or on safety or efficacy data submitted in support of the prior approval)
of such Product as determined by the applicable Regulatory Authority. A product licensed or produced by Licensee or any of its Affiliates,
under the same Regulatory Approval Application for the Product (i.e., an authorized generic product) will not constitute a Generic Product.

 

“Good Clinical Practices”
or “GCP” means the international ethical and scientific quality standard for the design, conduct, performance, monitoring,
auditing, recording, analyses and reporting of clinical trials as set out in the latest guidelines entitled “Guidance for Industry
E6” “Guideline for Good Clinical Practice”, and all applicable equivalent regulatory requirements imposed, adopted and
promulgated by the applicable Regulatory Authority in territories within the Licensee Territory for current good clinical practice, as
all such standards, practices and procedures may be updated or amended from time to time.

 

“Governmental Authority”
means any federal, national, state, provincial or local government, or political subdivision thereof, or any multinational organization
or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or
taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral
body) with jurisdiction over the Parties and the activities contemplated under this Agreement.

 

“Improvements”
has the meaning set forth in Section 2.3.

 

“Indemnified Party”
has the meaning set forth in Section 10.4.

 

“Indemnifying Party”
has the meaning set forth in Section 10.4.

 

“Indication”
means any disease, symptom, syndrome and medical condition that can be diagnosed, treated, prevented or ameliorated.

 

“Information”
means any data, results, approvals, technology, or information, in any tangible or intangible form, including know-how, trade secrets,
practices, techniques, methods, processes, inventions, ideas, drawings, developments, specifications, formulations, formulae, materials
or compositions of matter of any type or kind (patentable or otherwise), software, algorithms, marketing reports, expertise, technology,
test data (including pharmacological, biological, chemical, biochemical, clinical test data and data resulting from pre-clinical and nonclinical
studies), stability data and other study data and procedures.

 

“Infringement”
has the meaning set forth in Section 8.2(a).

 

    	 	4	 

     

    

 

“Initial Term”
has the meaning set forth in Section 12.1.

 

“Launch Date”
means the earlier of (i) the date on which Licensee commences its Commercialization efforts of the Product to customers after Regulatory
Approvals have been obtained in the Licensee Territory or (ii) thirty (30) days from the date that Regulatory Approvals for the Product
have been obtained in the Licensee Territory.

 

“Laws”
means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal,
national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign, anywhere in the world.

 

“Licensed Indication”
means the treatment, prevention, or amelioration of diarrhea in dogs.

 

“Licensed IP”
means, collectively, the Licensed Patents and the Licensed Know-How.

 

“Licensed Know-How”
means all Information (including regulatory data, files, approvals and other documentation) owned or Controlled by Licensor or any of
its Affiliates before or on the Effective Date or at any time during the Term, in each case, that is (a) generally not known and
(b) useful to the Commercialization of the Product for the Licensed Indication in the Licensee Territory, but excluding any Information
to the extent described in any published Licensed Patent.

 

“Licensed Patents”
means any Patent that: (a) covers the Product or its Commercialization for the Licensed Indication in the Licensee Territory, (b) is
owned or Controlled by Licensor or any of its Affiliates and (c) is issued or filed before or on the Effective Date or at any time
during the Term, but excluding any Licensee Arising Patents. The Licensed Patents existing as of the Effective Date are set forth in Exhibit A
hereto.

 

“Licensee Arising
IP” means, collectively, Licensee Arising Patents and Licensee Arising Know-How.

 

“Licensee Arising
Know-How” means all Information (including regulatory data, files, approvals and other documentation) owned or Controlled by
Licensee to the extent derived from Licensee’s activities under this Agreement that is useful for the Development or Commercialization
of Crofelemer and/or the Product, but excluding any Information derived from the performance of the Services.

 

“Licensee Arising
Patents” all Patents owned or Controlled by Licensee to the extent derived from Licensee’s activities under this Agreement
that is useful for the Development or Commercialization of Crofelemer and/or the Product, but excluding any Information derived from the
performance of the Services.

 

“Licensee Indemnitees”
has the meaning set forth in Section 10.1.

 

“Licensee Territory”
means the People’s Republic of China, excluding Hong Kong; provided that the Licensee Territory may be expanded, as mutually agreed
upon by the Parties, and as evidenced in a written amendment to this Agreement.

 

    	 	5	 

     

    

 

“Licensor Indemnitees”
has the meaning set forth in Section 10.2.

 

“Licensor Territory”
means worldwide other than the Licensee Territory.

 

“Licensor Trademarks”
means the Trademarks Controlled by Licensor or its Affiliates, whether registered or unregistered in any country in the Licensee Territory
that are set forth in Exhibit B hereto.

 

“Liens”
has the meaning set forth in Section 9.2(a).

 

“Major Market Countries”
means each of the Licensee Territory, the United States, the countries in the European Union, and the United Kingdom.

 

“Manufacturing Cost
Price” means, with respect to the Product provided by Licensor to Licensee, the actual costs and expenses borne by Licensor
to acquire the Product from Third Party manufacturers, including, without limitation, transportation to Licensee, plus a markup of fifteen
percent (15%).

 

“Maximum Service
Fee Amount” means, with respect to each Service Payment Date, the maximum amount in cash to be paid by Licensor to Licensee
or the maximum dollar value of Service Shares to be issued by Licensor to Licensee, as the case may be, on such Service Payment Date as
specified in Exhibit C hereto.

 

“Minimum Price”
means, with respect to a given date, the lower of: (i) the closing price (as reflected on Nasdaq.com) immediately preceding such
date or (ii) the average closing price of the Common Stock (as reflected on Nasdaq.com) for the five (5) trading days immediately
preceding such date.

 

“Net Profits”
means the Net Sales of the Product less (i) the Manufacturing Cost Price for such Product, (ii) the applicable costs for Commercialization
as well as an allocation of Overhead based on the time, expenses, and resources devoted to the Product-related activities, and (iii) any
customary and reasonable costs incurred in connection with the sale of the Product.

 

“Net Sales”
means, with respect to any given period, all revenues without limitation from the sale of Product, also called gross sales, by Licensee
and its Affiliates to Third Parties, less deductions for normal and customary trade, quantity and cash discounts and sales returns and
allowances. For purposes of determining Net Sales, the Product shall be deemed to be sold when invoiced and a “sale” shall
not include transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory or governmental purposes to the
extent no amount is received by Licensee or its Affiliates in connection therewith.

 

“OFAC”
has the meaning set forth in Section 9.3(h).

 

“Overhead”
means all customary and usual operating expenses directly related to the Product incurred by and in support of the particular manufacturing
cost centers, purchasing department and quality assurance operations specifically related to the Product (including labor, related payroll
taxes and employee benefits), depreciation, general taxes, rent, repairs and maintenance, supplies, utilities and factory administrative
expense.

 

    	 	6	 

     

    

 

“Patents”
means any and all (a) patent applications and issued patents, including, all national, regional, and international patents and patent
applications; provisionals; continuations; divisionals; continuations-in-part; continued prosecution applications; reissues, renewals,
substitutions, reexaminations, and revivals thereof; (b) patents that have issued or in the future issue from the foregoing patent
applications, including utility models, petty patents and design patents and certificates of invention; and (c) extensions (including
pediatric exclusivity, patent term extension and supplementary patent certificate) or restorations of the patents described above by existing
or future extension or restoration mechanisms.

 

“Personnel”
means employees, agents and other personnel of Licensee, its Affiliates or any subcontractors engaged to perform the Services.

 

“Pharmacovigilance
Agreement” has the meaning set forth in Section 5.7.

 

“Profit-Sharing Report”
has the meaning set forth in Section 7.2.

 

“Product”
means a canine-specific pharmaceutical product for the Licensed Indication that utilizes Crofelemer as its active drug substance marketed
in the United States under the Trademark Canalevia®, Canalevia-CA1 and Canalevia CA-2.

 

“Product Labeling”
means, with respect to the Product: (a) the Regulatory Authority-approved full prescribing information for the Product for a country
or other jurisdiction, including any required patient information; and (b) all labels and other written, printed, or graphic matter
upon a container, wrapper or any package insert utilized with or for the Product in such country or other jurisdiction.

 

“Pro Rata Percentage”
means (a) with respect to Licensee, forty percent (40%) and (b) with respect to Licensor, sixty percent (60%), subject to adjustment
pursuant to Section 5.5(c).

 

“Publication”
has the meaning set forth in Section 11.4.

 

“Quarter”
means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1,
except that the first Quarter of the Term commences on the Effective Date and ends on the day immediately before the first to occur of
January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter ends on the last day
of the Term.

 

“Monthly License
Fee” has the meaning set forth in Section 7.1.

 

“Monthly Service
Fee” means the fee for the Services to be paid either in cash or in unregistered, restricted shares of Common Stock (the “Service
Shares”), at the sole discretion of Licensor, in the amounts and according to the schedule set forth in Exhibit C
hereto.

 

“OFAC”
has the meaning set forth in Section 9.3(h).

 

“Receiving Party”
has the meaning set forth in Section 11.1(a).

 

    	 	7	 

     

    

 

“Regulatory Approval”
means, with respect to a particular country and product, a marketing authorization granted by the applicable Regulatory Authority in such
country for such product, including, where applicable, (a) pricing or reimbursement approval in such country or other jurisdiction,
(b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto)
and (c) approval of Product Labeling.

 

“Regulatory Approval
Application” means an application to the applicable Regulatory Authority for approval to Commercialize the Product in a particular
jurisdiction in the Licensee Territory.

 

“Regulatory Authority”
means, with respect to a particular country or jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approvals
of pharmaceutical products in such country or jurisdiction.

 

“Regulatory Expenses”
has the meaning set forth in Section 5.1(a).

 

“Regulatory Materials”
means Regulatory Approval Applications, investigational new drug applications, clinical trial applications, submissions, notifications,
communications, correspondence, registrations, Regulatory Approvals or other filings made to, received from or otherwise conducted with
a Regulatory Authority to Commercialize the Product in a particular country or jurisdiction.

 

“Reimbursement Cap”
means Two Million Dollars (US$2,000,000).

 

“Reimbursement Shares”
has the meaning set forth in Section 5.5(c).

 

“Renewal Term”
has the meaning set forth in Section 12.1.

 

“SDN List”
has the meaning set forth in Section 9.3(h).

 

“Securities Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Service Payment
Date” has the meaning set forth in Section 5.5(a).

 

“Service Share Amount”
means, for each Service Payment Date, a number of Service Shares determined by dividing the Maximum Service Fee Amount for such Service
Payment Date by the Minimum Price on such Service Payment Date.

 

“Service Shares”
has the meaning set forth in the defined term “Monthly Service Fee.”

 

“Services”
has the meaning set forth in Section 5.1(a).

 

“Shares”
means collectively, the Service Shares and the Reimbursement Shares.

 

“Term”
has the meaning set forth in Section 12.1.

 

“Third Party”
means any person other than a Party or an Affiliate of a Party.

 

    	 	8	 

     

    

 

“Trademark”
means any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier, including
any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain names, whether or not registered.

 

“Valid Claim”
means a claim of (a) any issued and unexpired patent whose validity, enforceability, or patentability has not been affected by any
of the following: (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer; or (ii) a holding,
finding, or decision of invalidity, unenforceability, or non-patentability; or (b) a pending patent application that is filed and
prosecuted in good faith and no more than ten (10) years have elapsed from its earliest priority date.

 

2.             License

 

2.1             Licensor
Grant to Licensee. Subject to the terms and conditions of this Agreement, Licensor hereby grants
to Licensee an exclusive (even as to Licensor), non-transferable, non-sublicensable license under the Licensed IP and the Licensor Trademarks
for Licensee to Commercialize the Product for the Licensed Indication in the Licensee Territory; provided, however, for
the avoidance of doubt, nothing in this Agreement grants Licensee the right to manufacture or have manufactured the Product for Commercialization
or any other purpose, as set forth in Section 4.1 hereof (Supply of Product).

 

2.2             Licensee
Grant to Licensor. Subject to the terms and conditions of this Agreement, Licensee hereby grants
to Licensor an exclusive (even as to Licensee), perpetual (subject to the termination rights of the Parties set forth in Section 12.3
(Effect of Termination)), transferable license under the Licensee Arising IP to Develop or Commercialize any product for any Indication
anywhere in the world (other than, with respect to Commercialization, the Product for the Licensed Indication in the Licensee Territory).
Licensor and its Affiliates shall have the right to sublicense the rights granted to it under this Section 2.2 to any Third
Party; provided, that, in each such case, Licensor shall be responsible for any such Third Party as if Licensor were exercising
such sublicensed rights itself under this Agreement.

 

2.3             No
Implied Licenses. Except as explicitly set forth in this Agreement, neither Party will be deemed
to have granted to the other Party any license or other right to any intellectual property of such Party, whether by estoppel, implication
or otherwise. Licensee acknowledges and agrees that as between Licensee and Licensor, except for the license granted under this Agreement,
Licensor retains all right, title and interest in and to the Licensed Patents, including all improvements and enhancements to the Licensed
Patents made or created by Licensee pursuant to this Agreement or made or created by or on behalf of Licensor during the Term (collectively,
 “Improvements”).

 

3.             Governance

 

3.1             Collaboration
Management. Each of the Parties shall appoint a single representative to act as that Party’s
collaboration manager (each, a “Collaboration Manager”).

 

    	 	9	 

     

    

 

3.2           Roles
and Responsibilities. The role of the Collaboration Manager is to act as a point of contact between
the Parties to assure a successful collaboration. The Collaboration Managers shall develop the strategies for and oversee the Commercialization
of the Product in the Licensee Territory. In particular, the Collaboration Managers shall: (a) develop the Commercialization Plan;
(b) review, discuss and implement all registration and regulatory activities in the Licensee Territory with respect to the Product;
and (c) perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement
or as mutually determined by the Parties in writing.

 

3.3           Substitutions.
Each Party may change its designated Collaboration Manager from time to time upon written notice to the other Party. Any Collaboration
Manager may designate a substitute to temporarily perform the functions of that Collaboration Manager by written notice to the other Party.

 

4.             Manufacturing
and Supply

 

4.1           Supply
of Product. Licensor shall be responsible for the supply of Product to Licensee at the Manufacturing
Cost Price in accordance with U.S. Current Good Manufacturing Practices. All Product supplied under this Agreement will be delivered FOB
Licensor’s designated warehouse located in the United States of America. Under no circumstance shall Licensee have the right or
obligation to manufacture Crofelemer or Product.

 

4.2           Responsibilities
of Collaboration Managers. Prior to the anticipated Launch Date of the Product in the Licensee
Territory, the Collaboration Managers shall agree on the quantities of Product that Licensor shall supply and such other terms and conditions
as they consider necessary or desirable to carry out the purposes of the foregoing. If Licensor is unable to meet such supply schedule
at any time, the Collaboration Managers shall discuss in good faith as to the cause(s) of such failure and confer on a resolution.

 

5.             ENGAGEMENT
FOR SERVICES

 

5.1           Scope
of Services.

 

(a)             Licensee
shall prepare, submit and obtain all Regulatory Approvals for the Product in the Licensee Territory on behalf of, and in the name of,
Licensor (the “Services”). Licensee shall perform the Services in accordance with the terms of this Agreement. During
the Initial Term, Licensee shall be solely responsible for all fees and expenses incurred by or on behalf of Licensee with respect to
the performance of the Services (collectively, “Regulatory Expenses”), subject to the Parties’ election for Licensor
to reimbursement Regulatory Expenses up to the Reimbursement Cap in accordance with Section 5.5(c) (Reimbursement
of Regulatory Expenses).

 

(b)             Upon
reasonable request from Licensee and as reasonably appropriate, Licensor shall compile all necessary data, documents and Regulatory Approvals
for the Product in the U.S. Licensee shall be responsible for any formatting or translations required by Regulatory Authorities in the
Licensee Territory, which formatting or translations Licensor shall have the right to review and edit.

 

(c)             To
the extent applicable, Licensee shall, if requested to do so by Licensor, represent Licensor in customs declaration, and satisfying and
completing any and all quality supervision, inspection and quarantine requirements and formalities relating to the product under Chinese
law free of any charge to Licensor.

 

    	 	10	 

     

    

 

(d)             If
and when Regulatory Approvals for the Product are secured, Licensee shall maintain and renew the Regulatory Approvals in the Licensee
Territory and pay all user fees and other costs required to obtain and maintain such Regulatory Approvals during the Initial Term.

 

(e)             Licensee
shall keep Licensor informed of developments relating to the Services and shall promptly notify Licensor in writing of any action or decision
by any Regulatory Authority in the Licensee Territory regarding the Services. Licensee shall provide Licensor for review and approval
all draft Regulatory Materials as soon as practicable in advance of their intended date of submission to a Regulatory Authority in the
Licensee Territory. Use of such Regulatory Materials may not be implemented until Licensor approval has been obtained. Once per Quarter,
Licensee shall provide the Collaboration Managers with a written report that sets forth (i) a summary and timeline for all ongoing
and planned Regulatory Activities, (ii) a summary of all material and substantive interactions with applicable Regulatory Authorities
for the Product in the Licensee Territory and (iii) updates on key milestones relating thereto.

 

(f)             Licensee
hereby agrees, upon request, to provide copies of all Regulatory Materials, Regulatory Approvals and all corresponding documentation to
Licensor as soon as practicable after Licensee’s submission to Regulatory Authorities, including English translations thereof prepared
by a Third Party translation service mutually agreed upon between the Parties.

 

5.2          Subcontracting;
Personnel. Licensee may subcontract the Services to any Third Party, and Licensee shall engage
qualified and experienced Personnel to perform the Services, and shall remain responsible for performance and/or breach of this Agreement
by Personnel. Licensee shall be solely responsible for all employer obligations toward Personnel under Applicable Laws, including compensation,
payroll taxes and benefits. Prior to performing any Services and/or receiving Confidential Information of Licensor, all Personnel must
(a) be subject to, and bound by, confidentiality obligations consistent with the terms of this Agreement, and (b) assign and
otherwise effectively vest in Licensee any and all rights that such Personnel might otherwise have in the results of their work.

 

5.3          Ownership.
As between Licensor and Licensee, all rights, title and interest to all Regulatory Approvals, reports, data, technical information, original
works of authorship and all other information, furnished by or on behalf of Licensor, or developed or provided by Licensee or Personnel
in connection with the Services under this Agreement, including all related data, materials, and other work product (collectively, the
 “Deliverables”), are “works made for hire” for Licensor under applicable copyright law and are the exclusive
property of Licensor. To the extent any Deliverables do not qualify as a “work made for hire,” Licensee hereby assigns to
Licensor all right, title and interest in such Deliverables, including all related intellectual property rights. At Licensor’s request
and expense, Licensee will sign documents and take any other action reasonably necessary to perfect or otherwise protect Licensor’s
rights in the Deliverables. Licensee will not incorporate any Third Party intellectual property into a Deliverable without Licensor’s
express written consent.

 

    	 	11	 

     

    

 

5.4          Cooperation.
Licensor shall provide reasonable cooperation to Licensee with respect to obtaining Regulatory Approval for the Product. Licensor hereby
grants to Licensee a right of reference to all Regulatory Materials filed by or on behalf of Licensor in the Licensor Territory or Licensee
Territory, which right of reference Licensee may use for the sole purpose of performing the Services. Licensor shall promptly submit any
necessary notices or authorizations to Regulatory Authorities that are necessary to effect such rights of reference.

 

5.5          Payment
Terms.

 

(a)             As
consideration for the Services, Licensor shall initiate payment to Licensee of a Monthly Service Fee on the second to last Business Day
of the applicable calendar month (except for the initial Monthly Service Fee, which shall be paid within three (3) Business Days
of the Effective Date) (each such date, a “Service Payment Date”) with delivery of such Monthly Service Fee to occur
no later than the second Business Day immediately following the end of the applicable calendar month; provided, however,
in no event shall the cumulative number of Shares issued to Licensee (i) exceed the Exchange Cap or (ii) result in Licensee,
together with its Affiliates and any other person or entity whose holdings would be aggregated with Licensee for purposes of Section 13(d) of
the Exchange Act, beneficially owning more than 19.99% of the issued and outstanding Common Stock, unless stockholder approval is obtained.

 

(b)             Service
Payment Notice. On each Service Payment Date, Licensor shall provide notice (by telephone or electronic mail) to Licensee of (i) whether
the Monthly Service Fee for the applicable month will be paid in cash or in the Service Shares, which election will be at Licensor’s
sole discretion, (ii) in the event of payment in cash, the actual amount of payment, and (iii) in the event of payment in the
Service Shares, (A) the Minimum Price on such Service Payment Date and (B) the Service Share Amount.

 

(c)             Reimbursement
of Regulatory Expenses. Upon mutual agreement of Licensor and Licensee, Licensor shall have the option, at any time during the Initial
Term, to reimburse Licensee for all Regulatory Expenses up to, but not exceeding, the Reimbursement Cap, with all Regulatory Expenses
in excess of the Reimbursement Cap and any additional fees and expenses incurred thereafter for maintaining the Regulatory Approvals to
be borne by Licensee. Licensee shall provide Licensor with an invoice for such amount, along with documentation evidencing the actual
payment made by Licensee with respect to the Regulatory Expenses. Licensor shall pay such invoice in cash or through the issuance of unregistered,
restricted shares of Common Stock of Licensor (the “Reimbursement Shares”) to Licensee (based on the Minimum Price
at the time of such election) within thirty (30) days of receipt of the invoice and accompanying documents; provided, however,
in no event shall the cumulative number of Shares issued to Licensee (i) exceed the Exchange Cap or (ii) result in Licensee,
together with its Affiliates and any other person or entity whose holdings would be aggregated with Licensee for purposes of Section 13(d) of
the Exchange Act, beneficially owning more than 19.99% of the issued and outstanding Common Stock, unless stockholder approval is obtained.
If Licensor has reimbursed Licensee for Regulatory Expenses incurred during the Initial Term as provided in this Section 5.5(c),
each Party’s Pro Rata Percentage of the Net Profits of the Product shall be adjusted to, with respect to Licensee, twenty percent
(20%) and, with respect to Licensor, eighty percent (80%).

 

    	 	12	 

     

    

 

(d)            Payment
through the Issuance of Shares. In the event Licensor elects to pay (i) the Monthly Service Fee in form of the Service Shares,
and/or (ii) the invoice for the Regulatory Expenses in the form of the Reimbursement Shares:

 

(i)             The
Shares shall be deemed fully vested, fully earned, not subject to forfeiture or rescission, free of any contingencies and fully paid for,
as of the issuance date, and Licensee shall be deemed to hold all investment risk therewith on such issuance date. Notwithstanding the
foregoing, the Shares will be unregistered and bear the restrictive legend set forth in Section 5.8 (Restrictive Legend).
Licensor shall have no obligation to register the Shares.

 

(ii)             To
facilitate the payment of Shares, Licensor shall open an account with its transfer agent and authorize the issuance of the Shares in book
entry form with the transfer agent. Licensor shall pay for any transfer agent and/or legal related costs that Licensee might incur in
the process of removing the trading restrictions from the Shares, which includes but is not limited to, Licensor providing a legal opinion
for the Shares, provided the Shares meet the requirements under the Securities Act for the removal of the restrictive legend described
in Section 5.8 (Restrictive Legend).

 

5.6          Notification
of Threatened Action. Each Party shall immediately notify the other Party of any information
it receives regarding any threatened or pending action, inspection or communication by or from any Regulatory Authority, which may affect
the Commercialization or Regulatory Approval of the Product.

 

5.7          Adverse
Event Reporting and Safety Data Exchange. No later than one hundred eighty (180) days following
the submission of the first Regulatory Approval Application for the Product in the Licensee Territory, the Parties shall define and finalize
the actions that the Parties shall employ with respect to the Product to protect patients and promote their well-being in a written pharmacovigilance
agreement (the “Pharmacovigilance Agreement”). In the event of any inconsistency between the provisions of the Pharmacovigilance
Agreement and the provisions of this Agreement, the wording of the Pharmacovigilance Agreement shall govern any and all patient safety
matters and this Agreement shall govern all other matters.

 

5.8          Restrictive
Legend. Each instrument evidencing the Shares which Licensee may acquire hereunder shall be imprinted
with a legend substantially in the following form:

 

“THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE ACT OR (B) AN OPINION OF COUNSEL, IN FORM REASONABLY ACCEPTABLE TO THE COMPANY,
THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.”

 

5.9           Legend
Removal. Licensor shall remove all restrictive legends from any Shares within ten (10) Business
Days of Licensee’s valid request made pursuant to Rule 144 of the Securities Act, or following the effective date of a registration
statement filed by Licensor covering the resale of such Shares (this in no way obligates Licensor to file a registration statement).

 

    	 	13	 

     

    

 

6.             Commercialization

 

6.1          Commercialization
Plan. The Commercialization of the Product in the Licensee Territory shall be conducted pursuant
to a strategy and plan (the “Commercialization Plan”), which the Collaboration Managers shall develop. The Commercialization
Plan shall include, with respect to the Licensee Territory, a high-level overview of:

 

(a)             general
strategies for the promoting, detailing, marketing and distributing of the Product;

 

(b)             pre-Launch
Date Commercialization activities and the expected Launch Date;

 

(c)             the
nature of promotional activities anticipated;

 

(d)             (i) summary-level
peak market forecasts and 24-month written rolling sales forecasts for the Product in the Licensee Territory, updated quarterly and (ii) performance
criteria for such sales forecasts (to be established by the Collaboration Managers two (2) years after the Launch Date of the Product
in the Licensee Territory); and

 

(e)             projections
of annual Net Profits for the Product.

 

6.2          Commercialization
Diligence. Following receipt of Regulatory Approval of the Product in the Licensee Territory,
Licensee shall Commercialize the Product for the Licensed Indication in the Licensee Territory in accordance with the Commercialization
Plan.

 

6.3          Responsibility
for Commercialization in the Licensee Territory. Subject to the terms and conditions of this
Article 6, Licensee shall have sole control over and decision-making authority for, at its cost and expense, implementing
the Commercialization Plan for the Product in the Licensee Territory. Licensee shall, with respect to the Product in the Licensee Territory,
have full ownership of and control over: (a) developing the strategy for, and negotiating with applicable Governmental Authorities
regarding, the price and, if any, reimbursement status of the Product; (b) marketing and promotion; (c) booking sales, and distribution
and performance of related services; (d) handling all aspects of order processing, invoicing and collection, inventory and receivables;
(e) providing customer support, including handling medical queries, and performing other related functions; and (f) conforming
its practices and procedures to applicable Laws relating to the marketing, detailing and promotion of the Product in the Licensee Territory.

 

6.4          Cross-Territorial
Restrictions.

 

(a)          Licensee
Restrictions. As permitted by Law, Licensee shall not, and shall ensure that its Affiliates will not, either directly or indirectly,
knowingly promote, market, distribute, import, sell or have sold the Product, including via internet or mail order, into the Licensor
Territory.

 

    	 	14	 

     

    

 

(b)          Licensor
Restrictions. As permitted by Law, Licensor shall not, and shall ensure that its Affiliates will not, either directly or indirectly,
knowingly promote, market, distribute, import, sell or have sold the Product, including via internet or mail order, into the Licensee
Territory.

 

7.            Compensation

 

7.1          Monthly
License Fee. As consideration for the license granted hereunder, Licensee shall make non-refundable
cash payments in the amounts and in accordance with the schedule set forth in Exhibit D (the “Monthly License Fee”)
to Licensor. Licensee shall pay the Monthly License Fee no later than the last Business Day prior to the end of the applicable calendar
month (except for the initial Monthly License Fee, which shall be paid within three (3) Business Days of the Effective Date). The
maximum aggregate amount payable by Licensee pursuant to this Section 7.1 is Five Million Dollars ($5,000,000). For clarity,
(i) following the Initial Term, no further Monthly License Fee shall be payable by Licensee and (ii) a breach of this Section 7.1
shall constitute a material breach of this Agreement for which the remedies of Section 12.2(b) (Termination for Material
Breach) shall be available to Licensor.

 

7.2          Profit-Sharing.
Each Party shall be entitled to receive its Pro Rata Percentage, subject to adjustment as provided in Section 5.5(c) (Reimbursement
of Regulatory Expenses), of aggregate Net Profits from sales of the Product in the Licensee Territory, on a quarterly basis. Within
sixty (30) days after each Quarter commencing with the Quarter upon which the Launch Date occurs, Licensee shall furnish consolidated
profit statements that show Net Sales and Net Profits of the Product for such Calendar Year, together with an itemized analysis of the
deductions from gross to Net Sales and number of units sold (less damaged, rejected, recalled or returned product), as well as the components
of each of the foregoing and calculations performed to calculate such Net Sales and Net Profits (the “Profit-Sharing Report”).
Concurrent with the delivery of the Profit-Sharing Report, Licensee shall remit payment to Licensor of Licensor’s Pro Rata Percentage
of aggregate Net Profits from sales of the Product in the Licensee Territory.

 

7.3          Currency;
Exchange Rate. All payments to be made by Licensee to Licensor under this Agreement, except for
payments through issuance of Shares, shall be made in Dollars by bank wire transfer in immediately available funds to a bank account designated
by written notice from Licensor. For the purpose of calculating any such sums due, Licensee shall convert any amount expressed in a foreign
currency into Dollar equivalents using its standard conversion methodology consistent with the International Financial Reporting Standards
as issued by the International Accounting Standards Board.

 

7.4          Late
Payments. If Licensor does not receive payment of any sum due to it on or before the due date
therefor, simple interest shall thereafter accrue on the sum due to Licensor from the due date until the date of payment at a rate per
annum (but with interest accruing on a daily basis) equal to the London Interbank Offered Rate, the successor thereto (if any), or the
highest rate allowable by applicable Law, whichever is less.

 

    	 	15	 

     

    

 

7.5          Taxes.

 

(a)          Taxes
on Income. Each Party shall pay all taxes imposed on its share of income arising directly or indirectly from the efforts of, or the
receipt of any payment by, such Party under this Agreement.

 

(b)          Tax
Cooperation. Each Party agrees to cooperate with the other Party and to use reasonable efforts to reduce or eliminate tax withholding
or similar obligations in respect of the Monthly License Fee and Monthly Service Fee made by such Party under this Agreement, as applicable.
Licensor shall provide Licensee with any tax forms that may be reasonably necessary in order for Licensee not to withhold tax or to withhold
tax at a reduced rate under an applicable bilateral income tax treaty a reasonable time prior to the date the applicable payment is due.
Licensee shall provide Licensor with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes, value added
taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Licensor.

 

7.6          Financial
Records and Audits. Licensee shall maintain complete and accurate records in sufficient detail
to permit Licensor to confirm the accuracy of payments under this Agreement. Upon reasonable prior notice, such records shall be open
for examination during regular business hours for a period beginning on the Effective Date until five (5) years from the termination
or expiry of this Agreement, at Licensor’s expense, not more often than once each Calendar Year, by an independent certified public
accounting firm selected by Licensor. Any such accounting firm shall not disclose Licensee’s Confidential Information to Licensor,
except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the payments under this
Agreement. If such audit reveals any underpayment, Licensee shall pay such amount within thirty (30) days after the date of the accountant’s
report, plus interest (as set forth in Section 7.4 (Late Payments)) from the original due date (unless challenged in
good faith by Licensee, in which case any dispute with respect thereto shall be resolved in accordance with Section 13.4 (Referral
of Disputes to Parties Executive Officers). If such audit reveals any overpayment, such amount shall be creditable against future
payments due under this Agreement (or promptly refunded to Licensee, if there is no future payment due). Licensor shall bear the full
cost of such audit unless such audit reveals an underpayment by Licensee of more than five percent (5%) of the amount actually due for
the audited time period, in which case Licensee shall reimburse Licensor for the costs for such audit.

 

8.            Intellectual
Property Matters

 

8.1          Patent
Prosecutions.

 

(a)          Licensed
Patents.

 

(1)          Licensor
shall have the right to, and shall use reasonable endeavors to, file, prosecute and maintain all Licensed Patents in the Licensee Territory,
at Licensor’s own cost and expense. For the purpose of this Article 8, “prosecution” shall include any post-grant
proceeding including patent interference proceeding, opposition proceeding and reexamination.

 

    	 	16	 

     

    

 

(2)          Licensor
shall consult with Licensee and keep Licensee reasonably informed of the status of the Licensed Patents in the Licensee Territory and
shall promptly provide Licensee with all material correspondence received from any Governmental Authority in connection therewith. In
addition, Licensor shall use reasonable endeavors to provide Licensee with drafts of all proposed material filings and correspondence
to any Governmental Authority with respect to the Licensed Patents in the Licensee Territory for Licensee’s review and comment prior
to the submission of such proposed filings and correspondences. Licensor shall confer with Licensee and consider in good faith Licensee’s
comments prior to submitting such filings and correspondences, but, for the avoidance of doubt, shall decide (in its absolute discretion)
whether to adopt any of Licensee’s comments.

 

(b)          Licensee
Patents. Licensee shall have the sole right to file, prosecute and maintain the Licensee Arising Patents in the Licensee Territory,
at Licensee’s cost and expense.

 

(c)          Cooperation
in Prosecution. Each Party shall provide the other Party all reasonable assistance and cooperation in the patent prosecution efforts
provided above in this Section 8.1, including providing any necessary powers of attorney and executing any other required
documents or instruments for such prosecution.

 

8.2          Patent
Enforcement.

 

(a)          Notification.
Each Party shall promptly notify the other party if it becomes aware of any alleged or threatened infringement by a Third Party of any
of the Licensed Patents (“Infringement”).

 

(b)          Enforcement
Right. Licensee shall have the first right to bring and control any legal action in connection with any Infringement in the Licensee
Territory at its own expense and as it reasonably determines appropriate. If Licensee decides not to enforce the Licensed Patents against
such Infringement, then Licensor shall have the right to bring and control any legal action in connection with such Infringement in the
Licensee Territory at its own expense as it reasonably determines appropriate.

 

(c)          Cooperation;
Expense and Recoveries. Upon request of the Party bringing the action under Section 8.2(b) (Enforcement Right),
the other Party will reasonably cooperate with such enforcing Party. The non-enforcing Party shall have the right to be represented in
such matter by counsel of its own choice and at its own expense. Any and all recoveries resulting from such enforcement action shall first
be applied to reimburse each Party’s costs and expenses in connection therewith, and any remaining recoveries shall be retained
by the enforcing Party; provided that, if Licensee is the enforcing Party, such remaining amounts shall be included in the Net
Sales and Net Profits subject to the profit share payment by Licensee to Licensor under Section 7.2 (Profit-Sharing).

 

8.3          Trademarks.

 

(a)          Coordination.
Licensee will notify Licensor of the Trademarks and trade dress it intends to use on the Product in the Licensee Territory. If in its
sole discretion the Licensee chooses to utilize the Licensor’s Trademark, such utilization will be coordinated by the Collaboration
Managers.

 

    	 	17	 

     

    

 

9.            Representation
and Warranties; Covenants

 

9.1          Representations
and Warranties of Each Party. Each Party represents and warrants to the other Party as of the
Effective Date and the Restatement Date that:

 

(a)          it
has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder; and

 

(b)          this
Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict
with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.

 

9.2          Representations
and Warranties of Licensor. Licensor represents and warrants to Licensee as of the Restatement
Date that:

 

(a)          Title;
Encumbrances. Licensor solely owns the entire right, title and interest in and to the Licensed IP, free and clear from any mortgages,
pledges, liens, security interests, conditional and installment sale agreement, encumbrances, charges or claim of any kind (collectively,
 “Liens”), except for Liens issued to lenders in connection with secured borrowings by Licensor or its Affiliates, and
it has the right to grant the licenses to Licensee as purported to be granted pursuant to this Agreement, and Licensor has not previously
granted any license or rights under the Licensed IP that is inconsistent with the license granted to Licensee hereunder;

 

(b)          Notice
of Infringement. In the three (3) years prior to the Effective Date, Licensor has not received any written notice from any Third
Party asserting or alleging that any research or development of the Product by or on behalf of Licensor prior to the Effective Date infringed
or misappropriated the intellectual property rights of such Third Party;

 

(c)          No
Proceeding. There are no pending, and to Licensor’s knowledge, no threatened, adverse actions, suits, claims, interferences
or formal governmental investigations involving the Product and/or the Licensed IP by or against Licensor or any of its Affiliates in
or before any Governmental Authority;

 

(d)          Licensed
Patents. (i) Exhibit A includes all Patents that are owned by or licensed to Licensor or its Affiliates as of the
Effective Date and are reasonably necessary for or directly related to Licensor in the Commercialization of the Product; (ii) none
of the Licensed Patents are subject to any pending, or to Licensor’s knowledge, threatened, re-examination, opposition, interference
or litigation proceedings; and (iii) to Licensor’s knowledge, there are no acts or omissions of Licensor that would (A) constitute
inequitable conduct, fraud or misrepresentation with respect to any Licensed Patents, or (B) render any Licensed Patents invalid
or unenforceable in whole or in part; and

 

(e)          Licensor
Trademarks and Trademark Applications. Licensor makes no representations or warranties regarding any Licensor Trademarks, which are
being licensed “AS IS, WHERE IS”.

 

    	 	18	 

     

    

 

9.3          Representations
and Warranties of Licensee. Licensee hereby represents and warrants as of the Restatement Date
and as of each Service Payment Date and each date on which Licensee receives the Reimbursement Shares that:

 

(a)          it
is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D under the Securities Act and
Licensee shall promptly notify Licensor of any changes to its status as an “accredited investor”;

 

(b)          neither
Licensee, nor any person or entity with whom Licensee shares beneficial ownership of the Shares, is subject to any of the “Bad Actor”
disqualifications described in Rule 506(d)(1)(i)-(viii) of the Securities Act;

 

(c)          Licensee
is acquiring the Shares for investment for Licensee’s own account, and not with a view to, or for resale in connection with, any
distribution thereof, and Licensee has no present intention of selling or distributing any of the Shares;

 

(d)          Licensee
has had an opportunity to discuss Licensor’s business, management and financial affairs with Licensor’s management and to
obtain any additional information which Licensee has deemed necessary or appropriate for deciding whether or not to acquire the Shares,
including an opportunity to receive, review and understand the information set forth in Licensor’s financial statements, capitalization
and other business information as Licensee deems prudent;

 

(e)          Licensee
has such knowledge and experience in financial and business matters, including investments in other emerging growth companies that such
individual or entity is capable of evaluating the merits and risks of the investment in the Shares and it is able to bear the economic
risk of such investment;

 

(f)           Licensee
acknowledges and agrees that the Shares must be held indefinitely unless it is subsequently registered under the Securities Act or an
exemption from such registration is available, and Licensee has been advised or is aware of the provisions of Rule 144 promulgated
under the Securities Act as in effect from time to time, which permits limited resale of securities purchased in a private placement subject
to the satisfaction of certain conditions, including, among other things: the availability of certain current public information about
Licensor and the resale occurring following the required holding period under Rule 144;

 

(g)          Licensee
acknowledges that: (i) Licensor is a U.S.-based issuer, (ii) that any Shares issued to Licensee hereunder shall be issued in
the United States; (iii) that Licensor is not an authority on the securities laws of other countries, (iv) that Licensor is
not, in any way, advising Licensee with respect to the Shares nor the securities laws of the People’s Republic of China, and (v) it
is solely Licensee’s responsibility to seek and obtain appropriate and necessary advice from a professional expert in the securities
laws, tax laws and all other laws of the People’s Republic of China applicable to the issuance of the Shares to Licensee and applicable
to Licensee’s ability to receive, and realize value from, the Shares;

 

    	 	19	 

     

    

 

(h)          neither
Licensee, any of its affiliates or beneficial owners, nor any person for whom Licensee is acting as agent or nominee, (i) appears
on the list of Specially Designated Nationals and Blocked Persons (“SDN List”) maintained by the Office of Foreign
Assets Control of the U.S. Treasury Department (“OFAC”), the list of Foreign Sanctions Evaders maintained by OFAC,
or any other lists of restricted parties maintained by the U.S. Government, nor are they otherwise a party with which any entity is prohibited
to deal under the laws of the United States, (ii) is directly or indirectly owned, individually or in aggregate, 50% or more by one
or more persons on the SDN List, (iii) is a senior foreign political figure or any immediate family member or close associate of
a senior foreign political figure or (iv) is identified as a terrorist organization on any other relevant lists maintained by governmental
authorities. Licensee further represents and warrants that the monies used to pay the Monthly License Fee are not derived from, invested
for the benefit of, or related in any way to, and that no monies or dividends received as a result of the investment in the Shares shall
be provided to or for the benefit of, the governments of, or persons within, any country (A) under a U.S. embargo enforced by OFAC,
(B) that has been designated as a “non-cooperative country or territory” by the Financial Action Task Force or (C) that
has been designated by the U.S. Secretary of the Treasury as a “primary money laundering concern.” Licensee further represents
and warrants that this Agreement and any related transactions are not designed or intended to evade or circumvent any applicable regulations
related to or oversight by the Committee on Foreign Investment in the United States (“CFIUS”). Licensee further represents
and warrants that it: (1) has conducted thorough due diligence with respect to all of its beneficial owners, (2) has established
the identities of all beneficial owners and the source of each of the beneficial owner’s funds and (3) shall retain evidence
of any such identities, any such source of funds and any such due diligence. Licensee further represents and warrants that Licensee does
not know or have any reason to suspect that (x) the monies used to pay the Monthly License Fee have been or will be derived from
or related to any illegal activities, including money laundering activities, or any such monies were, or will be, directly or indirectly
derived from activities that may contravene federal, state or international laws and regulations, including anti-money laundering laws
and regulations, and (y) the proceeds from Licensee’s investment in the Shares will be used to finance any illegal activities;

 

(i)          Licensee
is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of the Shares and other activities
with respect to the Common Stock by the Licensee; and

 

(j)          Licensee,
together with its Affiliates and any other person or entity whose holdings would be aggregated with Licensee for purposes of Section 13(d) of
the Exchange Act, will not, after giving effect to any Shares issued or issuable on such date, beneficially own more than 19.99% of the
issued and outstanding Common Stock as of such date.

 

If at any time during the
Term, the representations and warranties set forth in this Section 9.3 cease to be true, Licensee shall promptly so notify
Licensor in writing.

 

9.4          Representations
and Warranties of Licensee, Licensee Guarantor and Parent.

 

(a)          Each
of Licensee, Licensee Guarantor and Parent hereby represents and warrants that it has, and shall continue to have at all times, the available
funds and/or capital commitments and financial ability necessary to timely fulfill Licensee’s obligations hereunder.

 

    	 	20	 

     

    

 

(b)          Licensee
Guarantor hereby represents and warrants as of the Restatement Date and as of each Service Payment Date and each date on which Licensee
receives the Reimbursement Shares that neither Licensee Guarantor nor any of its affiliates or beneficial owners, nor any person for whom
Licensee Guarantor is acting as agent or nominee, (i) appears on the SDN List maintained by OFAC, the list of Foreign Sanctions Evaders
maintained by OFAC, or any other lists of restricted parties maintained by the U.S. Government, nor are they otherwise a party with which
any entity is prohibited to deal under the laws of the United States, (ii) is directly or indirectly owned, individually or in aggregate,
50% or more by one or more persons on the SDN List, (iii) is a senior foreign political figure or any immediate family member or
close associate of a senior foreign political figure or (iv) is identified as a terrorist organization on any other relevant lists
maintained by governmental authorities. Licensee Guarantor further represents and warrants that the monies used to pay the Monthly License
Fee are not derived from, invested for the benefit of, or related in any way to, and that no monies or dividends received as a result
of the investment in the Shares shall be provided to or for the benefit of, the governments of, or persons within, any country (A) under
a U.S. embargo enforced by OFAC, (B) that has been designated as a “non-cooperative country or territory” by the Financial
Action Task Force or (C) that has been designated by the U.S. Secretary of the Treasury as a “primary money laundering concern.”
Licensee Guarantor further represents and warrants that this Agreement and any related transactions are not designed or intended to evade
or circumvent any applicable regulations related to or oversight by CFIUS. Licensee Guarantor further represents and warrants that it:
(1) has conducted thorough due diligence with respect to all of its beneficial owners, (2) has established the identities of
all beneficial owners and the source of each of the beneficial owner’s funds and (3) shall retain evidence of any such identities,
any such source of funds and any such due diligence. Licensee Guarantor further represents and warrants that Licensee Guarantor does not
know or have any reason to suspect that (x) the monies used to pay the Monthly License Fee have been or will be derived from or related
to any illegal activities, including money laundering activities, or any such monies were, or will be, directly or indirectly derived
from activities that may contravene federal, state or international laws and regulations, including anti-money laundering laws and regulations,
and (y) the proceeds from Licensee’s investment in the Shares will be used to finance any illegal activities.

 

(c)          Parent
hereby represents and warrants as of the Restatement Date and as of each Service Payment Date and each date on which Licensee receives
the Reimbursement Shares that neither Parent nor any of its affiliates or beneficial owners, nor any person for whom Parent is acting
as agent or nominee, (i) appears on the SDN List maintained by OFAC, the list of Foreign Sanctions Evaders maintained by OFAC, or
any other lists of restricted parties maintained by the U.S. Government, nor are they otherwise a party with which any entity is prohibited
to deal under the laws of the United States, (ii) is directly or indirectly owned, individually or in aggregate, 50% or more by one
or more persons on the SDN List, (iii) is a senior foreign political figure or any immediate family member or close associate of
a senior foreign political figure or (iv) is identified as a terrorist organization on any other relevant lists maintained by governmental
authorities. Parent further represents and warrants that the monies used to pay the Monthly License Fee are not derived from, invested
for the benefit of, or related in any way to, and that no monies or dividends received as a result of the investment in the Shares shall
be provided to or for the benefit of, the governments of, or persons within, any country (A) under a U.S. embargo enforced by OFAC,
(B) that has been designated as a “non-cooperative country or territory” by the Financial Action Task Force or (C) that
has been designated by the U.S. Secretary of the Treasury as a “primary money laundering concern.” Parent further represents
and warrants that this Agreement and any related transactions are not designed or intended to evade or circumvent any applicable regulations
related to or oversight by CFIUS. Parent further represents and warrants that Licensee Guarantor does not know or have any reason to suspect
that (x) the monies used to pay the Monthly License Fee have been or will be derived from or related to any illegal activities, including
money laundering, or any such monies were, or will be, directly or indirectly derived from activities that may contravene federal, state
or international laws and regulations, including anti-money laundering laws and regulations, and (y) the proceeds from Licensee’s
investment in the Shares will be used to finance any illegal activities.

 

    	 	21	 

     

    

 

9.5          Disclaimer.
EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 9, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN
BY OR ON BEHALF OF Licensor OR Licensee; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.

 

9.6          Covenants.

 

(a)          Compliance
with Law. Each Party covenants that in performing its obligations or exercising its rights under this Agreement: (a) it shall
comply with all applicable Laws, industry guidance and codes of practice; and (b) it shall not employ or engage any person or entity
who has been debarred or disqualified by any Regulatory Authority or, to its knowledge, is the subject of debarment or disqualification
proceedings by any Regulatory Authority.

 

(b)          No
Short Sales. No short sales shall be permitted by Licensee or its Affiliates during the period commencing on the Effective Date and
continuing through the termination of this Agreement.

 

(c)          Share
Ownership Disclosure. Upon the written or oral request of Licensor, Licensee shall, within one (1) Business Day confirm orally
and in writing to Licensor the number of shares of Common Stock then beneficially owned by Licensee, together with Licensee’s Affiliates
and any other person or entity whose holdings would be aggregated with Licensee for purposes of Section 13(d) of the Exchange
Act.

 

(d)          Lock-Up.
Without prejudice and in addition to any other transfer restrictions specified in this Agreement, Licensee agrees not to sell, transfer,
loan, grant any option for the purchase of, or otherwise dispose of (collectively, a “Transfer”) any Shares acquired
by Licensee pursuant to this Agreement until after the 90-day period following the date of such acquisition.

 

10.          Indemnification;
Liability; INSURANCE

 

10.1        Indemnification
by Licensor. Licensor shall indemnify and hold Licensee, its Affiliates, and their respective
officers, directors, agents and employees (“Licensee Indemnitees”) harmless from and against any claim, suit, action
or other legal proceeding brought by a Third Party (collectively, “Claims”) against them arising or resulting from:
(a) the negligence or willful misconduct of any of the Licensor Indemnitees; (b) the breach of this Agreement by Licensor, including
any warranties or representations made by Licensor to Licensee under this Agreement; or (c) the Development or Commercialization
of Crofelemer and/or the Product by or on behalf of Licensor or any of its Affiliates or licensees prior to the Effective Date; except
in each case, to the extent such Claims result from the activities set forth in Section 10.2 (Indemnification by Licensee)
for which Licensee is obligated to indemnify Licensor Indemnitees.

 

    	 	22	 

     

    

 

10.2        Indemnification
by Licensee. Licensee shall indemnify and hold Licensor, its Affiliates and their respective
trustees, officers, directors, agents and employees (“Licensor Indemnitees”) harmless from and against any Claims against
them arising or resulting from: (a) the negligence or willful misconduct of any of the Licensee Indemnitees; (b) the breach
of this Agreement by Licensee, including any warranties or representations made by Licensee to Licensor under this Agreement; (c) the
Commercialization of the Product by or on behalf of Licensee or any of its Affiliates or sublicensees after the Effective Date and (d) the
performance of the Services by or on behalf of Licensee or any of its Affiliates or sublicensees after the Effective Date; except in each
case, to the extent such Claims result from the activities set forth in Section 10.1 (Indemnification by Licensor)
for which Licensor is obligated to indemnify Licensee Indemnitees.

 

10.3        Indemnification
by Licensee Guarantor and Parent. Licensee Guarantor and Parent shall indemnify and hold Licensor
Indemnitees harmless from and against any Claims against them arising or resulting from the breach of any warranties or representations
made by Licensee Guarantor and Parent to Licensor under this Agreement; except to the extent such Claims result from the activities set
forth in Section 10.1 (Indemnification by Licensor) for which Licensor is obligated to indemnify Licensee Indemnitees.

 

10.4        Indemnification
Procedure. If a Party is seeking indemnification under Section 10.1 (Indemnification
by Licensor), 10.2 (Indemnification by Licensee) or 10.3 (Indemnification by Licensee Guarantor and Parent)
(the “Indemnified Party”), it shall inform the Party or Parties from which it is seeking indemnification (the “Indemnifying
Party”) of the Claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable
after receiving notice of the Claim. The Indemnifying Party shall have the right to assume the defense of any such Claim for which it
is obligated to indemnify the Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying
Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified
Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any Claim that has been
assumed by the Indemnifying Party. No Party shall have the obligation to indemnify any other Party in connection with any settlement made
without the Indemnifying Party’s written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot
agree as to the application of Section 10.1 (Indemnification by Licensor), 10.2 (Indemnification by Licensee)
or 10.3 (Indemnification by Licensee Guarantor and Parent) to any Claim, pending resolution of the dispute pursuant to Section 13.4
(Referral of Disputes to Parties Executive Officers), the Parties may conduct separate defenses of such Claims, with each Party
retaining the right to claim indemnification from any other Party in accordance with Section 10.1 (Indemnification by Licensor),
10.2 (Indemnification by Licensee) or 10.3 (Indemnification by Licensee Guarantor and Parent) upon resolution
of the underlying Claim.

 

10.5        Mitigation
of Loss. Each Indemnified Party shall take and shall procure that its Affiliates take all such
reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims
(or potential losses or damages) under this Article 10. Nothing in this Agreement shall or shall be deemed to relieve any
Party of any common law or other duty to mitigate any losses incurred by it.

 

    	 	23	 

     

    

 

10.6        Limitation
of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
PUNITIVE, OR INDIRECT DAMAGES (INCLUDING CONSEQUENTIAL OR INCIDENTAL LOSS OF PROFIT, LOSS OF OPPORTUNITY OR LOSS OF USE) ARISING FROM
OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS SECTION 10.6 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY
UNDER SECTION 10.1 (INDEMNIFICATION BY LICENSOR), 10.2 (INDEMNIFICATION BY LICENSEE) OR 10.3 (INDEMNIFICATION
BY LICENSEE GUARANTOR AND PARENT), OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 11
(CONFIDENTIALITY; PUBLICATION).

 

10.7        Insurance.
Licensee shall cooperate with Licensor to procure and maintain insurance, including product liability insurance, at Licensee’s sole
cost and expense, in a manner adequate to cover Licensee obligations hereunder and consistent with normal business practices of prudent
companies similarly situated at all times during which the Product is being commercially distributed or sold by Licensee hereunder. Licensee
shall name Licensor and its Affiliates as an additional insured on each such policy. Such insurance does not create a limit of Licensee’s
liability with respect to its indemnification obligations under this Article 10. Licensee shall provide Licensor with written
evidence of such insurance upon request. In the event of any notice of cancellation or non-renewal of such insurance, Licensee will take
all necessary steps to ensure continuity of coverage and provide to Licensor written disclosure thirty (30) days in advance of such cancellation
or non-renewal.

 

11.          Confidentiality;
Publication

 

11.1        Duty
of Confidence. Subject to the other provisions of this Article 11:

 

(a)        all
Confidential Information disclosed by a Party (the “Disclosing Party”) or its Affiliates under this Agreement shall
be maintained in confidence and otherwise safeguarded by the recipient Party (the “Receiving Party”), in the same manner
and with the same protection as such Receiving Party maintains its own confidential information;

 

(b)        the
Receiving Party may only use any such Confidential Information for the purposes of performing its obligations or exercising its rights
under this Agreement;

 

(c)        the
Receiving Party may disclose Confidential Information of the other Party to: (i) its Affiliates and sublicensees; and (ii) employees,
directors, agents, contractors, consultants and advisers of the Receiving Party and its Affiliates and sublicensees, (iii) to such
Party’s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys,
independent accountants or financial advisors to provide advice to such Party, in each case to the extent reasonably necessary for the
purposes of, and for those matters undertaken pursuant to, this Agreement; provided that such persons are bound to maintain the confidentiality
of, and non-use obligations in respect of, the Confidential Information in a manner consistent with the confidentiality provisions of
this Agreement; and

 

    	 	24	 

     

    

 

(d)        the
Receiving Party may disclose Confidential Information of the other Party to actual or potential investors, acquirers, collaborators, licensees,
sublicensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment,
acquisition, collaboration or licensing or sublicensing arrangement in connection with the Receiving Party; provided that such
persons are bound to maintain the confidentiality of, and non-use obligations in respect of, the Confidential Information in a manner
consistent with the confidentiality provisions of this Agreement, provided that the duration may be shorter if consistent with applicable
industry norms.

 

11.2        Exceptions.
The foregoing obligations in Section 11.1 (Duty of Confidence) shall not apply to the extent that the Receiving Party
can demonstrate that such Confidential Information:

 

(a)        is
known by the Receiving Party at the time of its receipt without an obligation of confidentiality, and not through a prior disclosure by
the Disclosing Party, as documented by the Receiving Party’s business records;

 

(b)        is
in the public domain before its receipt from the Disclosing Party, or thereafter enters the public domain through no fault of the Receiving
Party;

 

(c)        is
subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality
to the Disclosing Party; or

 

(d)        is
developed by the Receiving Party independently and without use of, or reference to, any Confidential Information received from the Disclosing
Party, as documented by the Receiving Party’s business records.

 

Any combination of features or disclosures shall
not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public
or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available
to the general public or in the rightful possession of the Receiving Party.

 

11.3        Authorized
Disclosures. Notwithstanding the obligations set forth in Sections 11.1 (Duty of Confidence)
and 11.5 (Security Exchange Disclosures), a Party may disclose the other Party’s Confidential Information to the extent
such disclosure is required by Law, judicial or administrative process, provided that in such event, the Receiving Party shall
promptly inform the Disclosing Party of such required disclosure and provide the Disclosing Party an opportunity to challenge or limit
the disclosure obligations. Confidential Information that is disclosed pursuant to this Section 11.3 shall remain otherwise
subject to the confidentiality and non-use provisions of this Article 11, and the Receiving Party disclosing Confidential
Information pursuant to Law or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a
protective order to ensure the continued confidential treatment of such Confidential Information.

 

    	 	25	 

     

    

 

11.4        Technical
Publication. The Parties shall ensure that all publications, and other forms of public disclosure
such as abstracts and presentations, of activities carried out under this Agreement or otherwise relating to the Product in the Licensee
Territory (each of the foregoing, a “Publication”) comply with the strategy established by the Collaboration Managers.

 

11.5        Security
Exchange Disclosures. Subject to Section 11.3 (Authorized Disclosures) above,
neither Party shall disclose the terms of this Agreement without the prior written consent of the other Party (which shall not be unreasonably
withheld or delayed) except as may be required by applicable Law in accordance with the requirements of this Section 11.5.
A Party may disclose the terms of this Agreement in securities filings with the Securities Exchange Commission (or equivalent foreign
agency) to the extent required by applicable Law after complying with the procedure set forth in this Section 11.5. In such
event, the Party seeking such disclosure shall prepare a draft confidential treatment request and redacted version of this Agreement to
request confidential treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than five (5) days
after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow
the Party seeking disclosure to file its request within the time lines proscribed by applicable Law. The Party seeking such disclosure
shall exercise reasonable endeavors to obtain confidential treatment of the Agreement from the Securities Exchange Commission (or equivalent
foreign agency) as represented by the redacted version reviewed by the other Party.

 

11.6        Press
Release and Use of Names. Each Party shall not make any public announcement concerning the entry
into this Agreement without the prior written consent of the other Party. Each Party shall have the right to use the other Party’s
name and logo in presentations, the company’s website, collateral materials, corporate overviews and other public disclosures contemplated
by Sections 11.3 (Authorized Disclosures) and 11.5 (Security Exchange Disclosures), in each case only to describe
the licensing relationship. Any other use by a Party of the other Party’s name and logo shall be subject to such other Party’s
prior written consent.

 

12.          Term
and Termination; SUSPENSION

 

12.1        Term.
The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 12,
shall expire upon the second anniversary of the Effective Date (the “Initial Term”). The Term will be automatically
be extended for successive two (2)-year terms (“Renewal Term”) and remain in effect until (i) the expiration of
the last-to-expire Valid Claim included in the Licensed Patents or Licensee Arising Patents, in each case, that claims the composition
of matter, manufacture, use or sale of Crofelemer in any Major Market Country; and (ii) the initiation of sales of a Generic Product
with respect to the Product in the Licensee Territory. The “Term” shall consist of the Initial Term and any Renewal
Terms. Upon the expiration of this Agreement, all rights and licenses granted hereunder shall terminate, provided that the license granted
by Licensee to Licensor under Section 2.2 (Licensee Grant to Licensor) for the Product in the Licensee Territory shall
continue and become fully-paid, perpetual and irrevocable.

 

    	 	26	 

     

    

 

12.2        Termination.

 

(a)        Termination
for Failure to Pay Monthly Service Fee. If Licensor fails to pay the Monthly Service Fee, then Licensee shall have the right, in its
sole discretion to terminate this Agreement effective on ninety (90) days’ written notice of termination to Licensor.

 

(b)        Termination
for Material Breach. If either Party believes that the other is in breach of its material obligations hereunder, then the non-breaching
Party may deliver notice of such breach to the other Party, and the allegedly breaching Party shall have sixty (60) days from such notice
to dispute or cure such breach. If the allegedly breaching Party fails to cure, or fails to dispute, that breach within such time period,
then the Party originally delivering the notice of breach may terminate this Agreement effective on written notice of termination to the
other Party.

 

(c)        Termination
for Insolvency. Subject to the applicable Bankruptcy Code in any country, each Party may terminate this Agreement in its entirety
upon immediate written notice if the other Party (i) applies for or consents to the appointment of, or the taking of possession by,
a receiver, custodian, trustee or liquidator of itself or of all or a substantial part of its property, (ii) makes a general assignment
for the benefit of its creditors, (iii) commences a voluntary case under the Bankruptcy Code of any country, (iv) files a petition
seeking to take advantage of any Laws relating to bankruptcy, insolvency, reorganization, winding-up, or composition or readjustment of
debts, (v) fails to controvert in a timely and appropriate manner, or acquiesce in writing to, any petition filed against it in any
involuntary case under the Bankruptcy Code of any country, (vi) takes any corporate action to effect any of the foregoing, (vii) has
a proceeding or case commenced against it in any court of competent jurisdiction, seeking (A) its liquidation, reorganization, dissolution
or winding-up, or the composition or readjustment of its debts, (B) the appointment of a trustee, receiver, custodian, liquidator
or the like of all or any substantial part of its assets, or (C) similar relief under the Bankruptcy Code of any country, or an order,
judgment or decree approving any of the foregoing is entered, and, in each case (A) through (C), such proceeding or case continues
unstayed for a period of sixty (60) days, or (viii) has an order for relief against it entered in an involuntary case under the Bankruptcy
Code of any country. All rights and licenses granted under or pursuant to this Agreement by each Party to the other Party, as applicable,
are and shall otherwise be deemed to be, for purposes of Section 365(n) of the Title 11, United States Code, as amended, licenses
of rights to “intellectual property” as defined under Article 101(35A) of the Bankruptcy Code.

 

(d)        Termination
for Lack of Regulatory Approval or Failure to Commercialize. In the event that Licensee (i) does not obtain Regulatory Approval
for the Product in the Licensee Territory prior to the fourth (4th) anniversary of the Effective Date or (ii) fails to
achieve sales of Product in the Licensee Territory that equals or exceeds seventy-five percent (75%) of the sales forecast set forth in
the Commercialization Plan in any Calendar Year and does not “cure” within sixty (60) days of notification from the Licensor,
then, in each case, Licensor may terminate this Agreement by providing ninety (90) days’ prior written notice thereof to Licensee.

 

(e)        Termination
for Failure to Initiate Regulatory Approval Process. In the event that Licensee does not conduct activities necessary or useful or
otherwise requested or required by a Regulatory Authority in support of obtaining Regulatory Approval during the Initial Term in a manner
that Licensor would normally take in its reasonable business discretion to accomplish a similar objective, Licensor may terminate this
Agreement by providing ninety (90) days’ prior written notice thereof to Licensee. For clarity, Licensor shall have the right to
terminate under this Section 12.2(e) where Licensee fails to initiate and engage in communications with Regulatory Authorities
in the Licensee Territory during the Initial Term.

 

    	 	27	 

     

    

 

(f)        Unilateral
Termination by Licensor. Notwithstanding any other provision of this Agreement, Licensor may terminate this Agreement in its entirety
by providing ninety (90) days’ prior written notice to Licensee.

 

(g)        Mutual
Termination. The Parties may mutually agree to terminate this Agreement at any time for any or no reason.

 

12.3        Effect
of Termination.

 

(a)        Return
or Destruction of Confidential Information. Upon the termination of this Agreement for any reason, each Party shall promptly return
or (at the other Party’s election) destroy and irretrievably erase all embodiments of the other Party’s Confidential Information
which are in its power, possession, custody or control; provided, that each Party may retain one copy of such Confidential Information
for the sole purpose of performing any continuing obligations hereunder or for archival purposes and shall continue to comply with the
terms of Article 11 (Confidentiality; Publication) in respect of the same.

 

(b)        Termination
by Licensee for Failure to Pay Monthly Service Fee, for Material Breach, or for Insolvency. If this Agreement is terminated by Licensee
pursuant to Section 12.2(a) (Termination for Failure to Pay Monthly Service Fee), Section 12.2(b) (Termination
for Material Breach), or Section 12.2(c) (Termination for Insolvency), then, in addition to the consequences
set forth in Section 12.3(a) (Return or Destruction of Confidential Information), (1) the license granted
by Licensor to Licensee under the Licensed IP and all rights relating thereto shall terminate; and (2) all amounts outstanding at
the date of termination shall immediately be due and payable. For clarity, any payment obligations arising in the calendar month when
this Agreement is terminated and all payment obligations due and payable or arising under this Agreement following the date of termination
shall be terminated and deemed null and void.

 

(c)        Termination
by Licensor for Material Breach, for Insolvency, for Lack of Regulatory Approval or Failure to Commercialize, or for Failure to Initiate
Regulatory Process, or Mutual Termination. If this Agreement is terminated by Licensor under Section 12.2(b) (Termination
for Material Breach), Section 12.2(c) (Termination for Insolvency), Section 12.2(d) (Termination
for Lack of Regulatory Approval or Failure to Commercialize), or Section 12.2(e) (Termination for Failure to Initiate
Regulatory Approval Process), or as mutually agreed to by the Parties under Section 12.2(g) (Mutual Termination),
then, in addition to the consequences set forth in Section 12.3(a) (Return or Destruction of Confidential Information),
(1) the license granted by Licensor to Licensee under the Licensed IP and all rights relating thereto shall terminate; (2) all
amounts outstanding at the date of termination shall immediately be due and payable; (3) Licensee shall grant to Licensor a fully
paid up, perpetual, sublicenseable, nonexclusive license, under Licensee Arising IP and Licensee Trademarks, for Licensor to Develop and
Commercialize the Product or any other products anywhere in the world; and (4) at Licensor’s request and expense, Licensee
shall transfer to Licensor all information and data relating to the Product, including but not limited to Regulatory Materials and related
data of the Product, in each case to the extent such information and data are included in the Licensee Arising IP. For clarity, any payment
obligations arising in the calendar month when this Agreement is terminated and all payment obligations due and payable or arising under
this Agreement following the date of termination shall be terminated and deemed null and void.

 

    	 	28	 

     

    

 

(d)        Unilateral
Termination by Licensor. If this Agreement is terminated by Licensor pursuant to Section 12.2(f) (Unilateral Termination
By Licensor), then, in addition to the consequences set forth in Section 12.3(c) (Termination by Licensor for
Material Breach, for Insolvency or Lack of Regulatory Approval or Failure to Commercialize, or for Failure to Initiate Regulatory Process,
or Mutual Termination), Licensor shall, within ninety (90) days of such termination, remit payment to Licensee in an amount equal
to one hundred twenty-five percent (125%) of the Regulatory Expenses incurred up through the date of receipt of the termination notice
delivered by Licensor to Licensee pursuant to Section 12.2(f) (Unilateral Termination By Licensor).

 

12.4        Survival.
Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.
Without limiting the foregoing, the provisions of Articles 1 (Definitions), 10 (Indemnification; Liability; Insurance)
and 13 (Miscellaneous), and Sections 7.4 (Late Payments), 7.6 (Financial Records and Audits),
8.1(b) (Licensee Patents), 8.1(c) (Cooperation in Prosecution), 11.1 (Duty of Confidence),
11.2 (Exceptions), 11.3 (Authorized Disclosures), 11.5 (Security Exchange Disclosures), 12.1
(Term), and 12.3 (Effect of Termination) and this Section 12.4 shall survive the expiration or termination
of this Agreement for any reason.

 

12.5        Suspension.
Licensor may, at its sole discretion, suspend its obligations under this Agreement except those under Article 11 (Confidentiality;
Publication), without terminating this Agreement, by providing written notice to Licensee at least three (3) days prior to the
date on which Licensor wishes to suspend (the “Suspension Date”). Licensee shall suspend any performance under this
Agreement related to Licensor’s obligations that are suspended after the Suspension Date until receipt of written notice from Licensor
to resume performance.

 

13.          Miscellaneous

 

13.1        Notices.
Unless otherwise provided in this Agreement, all notices permitted or required under this Agreement
shall be in writing and shall be delivered personally, sent by facsimile with a hard copy confirmation of receipt, or sent by express
delivery service to the address provided by each of Licensor, Licensee and Licensee Guarantor from time to time. Notices shall be effective
upon receipt in the case of personal delivery, on the date of the hard copy confirmation of receipt in the case of delivery by facsimile
or on the date the notice is delivered to the applicable address in the case of delivery by express overnight service.

 

13.2        Successors
and Assigns. This Agreement or any of the severable rights and obligations inuring to the benefit
of or to be performed by Licensor hereunder may be assigned by Licensor to a Third Party, including its Affiliates, in whole or in part,
without the need to obtain Licensee’s consent thereto. Licensee may not assign its rights or obligations under this Agreement or
delegate its duties hereunder without the prior written consent of Licensor.

 

    	 	29	 

     

    

 

13.3        Independent
Contractors. In performing this Agreement, each of the Parties will operate as, and have the
status of, an independent contractor. This Agreement does not create any agency, employment, partnership, joint venture, franchise or
other similar or special relationship between the Parties. Neither Party will have the right or authority to assume or create any obligations
or to make any representations, warranties or commitments on behalf of the other Party or its affiliates, whether express or implied,
or to bind the other Party or its affiliates in any respect whatsoever.

 

13.4        Referral
of Disputes to Parties Executive Officers. In the event of any disputes, controversies or differences
between the Parties arising out of, in relation to, or in connection with this Agreement, including any alleged failure to perform, or
breach, of this Agreement, or any issue relating to the validity, construction, interpretation, enforceability, breach, performance, application,
suspension, or termination of this Agreement a (“Dispute”), then upon the written request of either Party, the Dispute
shall be first submitted to the Executive Officers of each Party for attempted resolution by good faith negotiations within thirty (30)
days. If the Dispute is not resolved within sixty (60) days following the written request for amicable resolution, then either Party may
then initiate dispute resolution under Section 13.5 (Arbitration of Claims).

 

13.5        Arbitration
of Claims. If the Parties do not fully settle a Dispute pursuant to Section 13.4
(Referral of Disputes to Parties Executive Officers) and a Party wishes to pursue the matter, each such Dispute shall be finally
settled under the Rules of Arbitration of the International Chamber of Commerce by three (3) arbitrators. Each Party shall appoint
one (1) arbitrator. If a Party fails to appoint an arbitrator within thirty (30) days of the commencement of the arbitration, such
appointment shall be made by the President of the ICC International Court of Arbitration. The two (2) arbitrators appointed in accordance
with the preceding sentences shall appoint the third arbitrator, who shall be the chairperson of the tribunal. If the two (2) arbitrators
fail to appoint the third arbitrator within thirty (30) days of the appointment of the second of the arbitrators, the appointment of the
third arbitrator shall be made by the President of the ICC International Court of Arbitration.

 

(a)        The
place, or legal seat, of the arbitration shall be San Francisco, California, and the language of the arbitration shall be English.

 

(b)        In
addition to the Rules of Arbitration of the International Chamber of Commerce, the Parties agree that the arbitration shall be conducted
in accordance with the IBA Rules on the Taking of Evidence in International Arbitration, as current on the date of the commencement
of any arbitration.

 

(c)        Subject
to Section 10.6 (Limitation of Liability) above, the arbitrators shall have the power to grant any interim or provisional
measures that they deem appropriate, including but not limited to injunctive relief and specific performance, and any interim or provisional
measures that the arbitrators order may be specifically enforced by any court of competent jurisdiction as a final award. Nothing herein,
however, shall authorize the arbitrators to act as amiable compositeurs or to proceed ex aequo et bono, and the arbitrators
shall have no authority to exercise rights of jura novit curia. Each party hereto retains the right to seek interim measures from
a judicial authority, and any such request shall not be deemed incompatible with the agreement to arbitrate or a waiver of the right to
arbitrate.

 

    	 	30	 

     

    

 

(d)        The
arbitrators may award to the prevailing Party, if any, as determined by the arbitrators, its costs and expenses, including reasonable
attorneys’ fees. Judgment upon any award rendered by the arbitrators may be entered in any court of competent jurisdiction.

 

No information concerning an
arbitration, beyond the names of the parties and the relief requested, may be unilaterally disclosed to a third party by any party unless
required by Law. Any documentary or other evidence given by a party or witness in the arbitration shall be treated as confidential by
any party whose access to such evidence arises exclusively as a result of its participation in the arbitration, and shall not be disclosed
to any third party (other than a witness or expert), except as may be required by Law. Any party who commences any judicial proceeding
in connection with an arbitration initiated hereunder shall endeavor to have the judicial record of any such proceeding sealed to the
extent permitted by Law.

 

13.6        Governing
Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the
State of California, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of California
or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of California. The Parties
agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods.

 

13.7        Severability.
If any provision of this Agreement or portion thereof is determined by a court of competent jurisdiction,
or declared under any law, rule or regulation of any government having jurisdiction over the Parties hereto, to be invalid, illegal
or otherwise unenforceable, then such provision will, to the extent permitted by the court or government not be voided but will instead
be construed to give effect to its intent to the maximum extent permissible under applicable law and the remainder of this Agreement will
remain in full force and effect according to its terms.

 

13.8        Entire
Agreement; Modification; Waiver. This Agreement, including the Exhibits, the Pharmacovigilance
Agreement (when executed) and any other documents delivered pursuant hereto or thereto constitute the entire agreement of the Parties
concerning the subject matter hereof and supersedes any and all prior or contemporaneous, written or oral negotiations, correspondence,
understandings and agreements, between the Parties respecting the subject matter of this Agreement (including the Original Agreement,
which is hereby amended, restated and replaced by the version signed by the Parties as of the Restatement Date). No supplement, modification
or amendment to this Agreement shall be binding unless evidenced by a writing signed by an authorized officer of each Party. No waiver
of any of the provisions of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar,
nor shall any waiver constitute a continuing waiver. No waiver shall be binding unless executed in writing by the Party making the waiver.

 

13.9        Execution;
Counterparts. This Agreement shall not be binding in whole or in part upon the Parties unless
and until duly executed by or on behalf of both Parties hereto. This Agreement may be executed in counterparts, each of which shall be
deemed to be an original instrument enforceable in accordance with its terms and all of which shall constitute but one and the same agreement
of the Parties.

 

    	 	31	 

     

    

 

13.10      Further
Assurances. Each Party shall do and perform, or cause to be done and performed, all such further
acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other Party
may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

13.11      Waiver
of Jury Trial. Each Party hereby waives to the fullest extent permitted by applicable Law, any
right it may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this
Agreement. Each Party (a) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise,
that such other party would not, in the event of litigation, seek to enforce that foregoing waiver, and (b) acknowledges that it
and the other Parties have been induced to enter into this Agreement, as applicable, by, among other things, the mutual waivers and certifications
in this Section 13.11.

 

13.12      English
Language and Mutual Drafting. This Agreement shall be written and executed in, and all other
communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall
not be an official version thereof, and in the event of any conflict in interpretation between the English version and such translation,
the English version shall control. This Agreement is the mutual product of the parties hereto,
and each provision hereof has been subject to the mutual consultation, negotiation, and agreement of each of the parties, and shall not
be construed for or against any party hereto.

 

13.13      Guaranty.
Licensee Guarantor irrevocably guarantees the performance of all financial obligations of Licensee
under the provisions of this Agreement. This is a guarantee of payment and performance of payment obligations, and not of collection,
and Licensee Guarantor acknowledges and agrees that this guarantee is full and unconditional, and no release or extinguishments of Licensee’s
applicable liabilities (other than in accordance with the terms of this Agreement), whether by decree in any bankruptcy proceeding or
otherwise, will affect the continuing validity and enforceability of this guarantee. If and each time that Licensee fails to make any
payment when it is due under or pursuant to this Agreement, Licensee Guarantor must at Licensor’s request (without requiring Licensor
first to take steps against Licensee) pay directly to Licensor the relevant amount as if it were the principal obligor in respect of that
amount.

 

13.14      Waiver
of Payments for September 2022. Notwithstanding anything to the
contrary in this Agreement, (i) Licensor hereby acknowledges and agrees that (A) the Monthly License Fee due and payable by
Licensee for September 2022 and (B) the obligation of Licensee to subscribe for and purchase the Subscription Shares (as defined
in the Original Agreement) for September 2022, as provided in the Original Agreement, are waived in full, and (ii) Licensee
hereby acknowledges and agrees that the Monthly Service Fee due and payable by Licensor for September 2022 is waived in full.

 

[Remainder of page intentionally
left blank; signature page follows]

 

    	 	32	 

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have caused this Agreement to be executed by their duly authorized officers or representatives as of the Restatement Date.

 

	 	LICENSOR:
	 	 
	 	Jaguar Health, Inc.
	 	 
	 	By: 	/s/ Lisa A. Conte
	 	Name: 	Lisa A. Conte
	 	Title:	 President & CEO
	 	 
	 	LICENSEE:
	 	 
	 	SynWorld Technologies
    Corporation
	 	 
	 	By:	/s/ Tao Wang
	 	Name: 	Tao Wang
	 	Title: 	CEO
	 	 
	 	LICENSEE GUARANTOR:
	 	 
	 	C&E Telecom,
LTD
	 	 
	 	By: 	/s/ Tao Wang
	 	Name: 	Tao Wang
	 	Title: 	General Manager
	 	 
	 	PARENT:
	 	 
	 	/s/ Tao Wang
	 	Tao Wang

 

[Signature Page to License
and Services Agreement]

 

     

     

    

 

EXHIBIT A

 

Licensed Patents

 

[Attached]

 

[Exhibit A to License
and Services Agreement]

 

     

     

    

 

EXHIBIT B

 

Licensor Trademarks

 

[Attached]

 

[Exhibit B to License
and Services Agreement]

 

     

     

    

 

EXHIBIT C

 

Monthly Service Fee

 

	Period	 	Maximum Service Fee Amount (US$)1	 
	June 2022	 	 	150,000	 
	July 2022	 	 	166,666.66	 
	August 2022	 	 	166,666.66	 
	September 2022	 	 	166,666.67	2 
	October 2022	 	 	166,666.66	 
	November 2022	 	 	166,666.66	 
	December 2022	 	 	166,666.67	 
	January 2023	 	 	166,666.66	 
	February 2023	 	 	166,666.66	 
	March 2023	 	 	166,666.67	 
	April 2023	 	 	166,666.66	 
	May 2023	 	 	166,666.66	 
	June 2023	 	 	166,666.67	 
	July 2023	 	 	250,000	 
	August 2023	 	 	250,000	 
	September 2023	 	 	250,000	 
	October 2023	 	 	250,000	 
	November 2023	 	 	250,000	 
	December 2023	 	 	250,000	 
	January 2024	 	 	450,000	 
	February 2024	 	 	450,000	 
	March 2024	 	 	450,000	 
	Total	 	 	5,000,000	3 

 

1.
Dollar amounts set forth in the table are maximum amounts only and the exact amount in cash payable or dollar value of shares issuable
for any given period shall be provided in the Service Payment Notice provided pursuant to Section 5.5(b) of the Agreement.

 

2. The Monthly Service Fee for September 2022
is waived in full pursuant to Section 13.14 of the Agreement.

 

3. The total amount of the Monthly Service Fees
for all the months shall decrease by an amount equal to the Monthly Service Fee for September 2022, pursuant to Section 13.14
of the Agreement.

 

[Exhibit C to
License and Services Agreement]

 

     

     

    

 

EXHIBIT D

 

Monthly License Fee

 

	Period	 	Monthly License Fee (US$)	 
	June 2022	 	 	150,000	 
	July 2022	 	 	166,666.66	 
	August 2022	 	 	166,666.66	 
	September 2022	 	 	166,666.67	1 
	October 2022	 	 	166,666.66	 
	November 2022	 	 	166,666.66	 
	December 2022	 	 	166,666.67	 
	January 2023	 	 	166,666.66	 
	February 2023	 	 	166,666.66	 
	March 2023	 	 	166,666.67	 
	April 2023	 	 	166,666.66	 
	May 2023	 	 	166,666.66	 
	June 2023	 	 	166,666.67	 
	July 2023	 	 	250,000	 
	August 2023	 	 	250,000	 
	September 2023	 	 	250,000	 
	October 2023	 	 	250,000	 
	November 2023	 	 	250,000	 
	December 2023	 	 	250,000	 
	January 2024	 	 	450,000	 
	February 2024	 	 	450,000	 
	March 2024	 	 	450,000	 
	Total	 	 	5,000,000	2 

 

1.
The Monthly License Fee for September 2022 is waived in full pursuant to Section 13.14 of the Agreement.

 

2. The total amount of the Monthly Licensee Fees
for all the months shall decrease by an amount equal to the Monthly License Fee for September 2022, pursuant to Section 13.14
of the Agreement.

 

[Exhibit D to License
and Services Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]